Repligen (RGEN) Tops Q3 EPS by 7c, Offers Guidance

Repligen (NASDAQ: RGEN) reported Q3 EPS of $0.23, $0.07 better than the analyst estimate of $0.16. Revenue for the quarter came in at $141.2 million versus the consensus estimate of $140.67 million.

GUIDANCE:

Repligen sees FY2023 EPS of $1.70-$1.76, versus the consensus of $1.74. Repligen sees FY2023 revenue of $635-645 million, versus the consensus of $646 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
• Rothschild Redburn Upgrades Apple (AAPL) to Buy